Mergers & Acquisitions ·
Johnson & Johnson completed the acquisition of Firefly Bio for $1 billion in cash and entered into a strategic…
JNJJohnson & Johnson
Johnson & Johnson completed the acquisition of Firefly Bio for $1 billion in cash and entered into a strategic collaboration with Sail Biomedicines, including an equity investment and an exclusive option to acquire Sail for $2.58 billion. These transactions are expected to dilute adjusted operational EPS and adjusted EPS by approximately $0.64 in 2026 ($0.46 from Firefly, $0.18 from Sail) and $1.36 in 2027. Consequently, the company updated its full-year 2026 guidance, lowering the midpoint for adjusted operational EPS to $10.94 (from $11.58), adjusted sales growth to a 6.2%-6.8% range, and estimated reported sales to a $100.8B-$101.4B range. Johnson & Johnson is a diversified healthcare company engaged in the research, development, manufacture, and sale of products in the pharmaceutical, medical devices, and consumer health sectors.